Article Text

PDF
Hyperuricaemia and gout: state of the art and future perspectives
  1. Nicola Dalbeth1,
  2. Alexander So2
  1. 1Bone and Joint Research Group, Department of Medicine, University of Auckland, Auckland, New Zealand
  2. 2Service of Rheumatology, Department of Musculoskeletal Medicine, University Hospital of Lausanne, Lausanne, Switzerland
  1. Correspondence to Professor Alexander So, Service de Rhumatologie, CHUV, 1011 Lausanne, Switzerland; alexanderkai-lik.so{at}chuv.ch

Abstract

Major progress has been made in the past decade in understanding the pathogenesis and treatment of gout. These advances include identification of the genetic and environmental risk factors for gout, recognition that gout is an important risk factor for cardiovascular disease, elucidation of the pathways regulating the acute gout attack and the development of novel therapeutic agents to treat both the acute and chronic phases of the disease. This review summarises these advances and highlights the research agenda for the next decade.

Statistics from Altmetric.com

Footnotes

  • Funding AS receives support from the Fonds National Suisse de Recherche.

  • Competing interests AS has received consulting fees from Novartis. ND has no competing interests to declare.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.